retatrutide phase 2 trial type 2 diabetes weight loss 🚨 BREAKING: Shows “Bariatric-Level” in 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most The most intensive medical obesity

10.1016/j.immuni.2021.11.015 30 OhtaM.MimoriK.FukuyoshiY.KitaY.MotoyamaK.YamashitaK.et al (2008)

X.HaebeS.LeeA

We report that while SEMA led to substantial weight loss, reduced tumor engraftment, blunted progression, and reduced tumor burden compared to Veh, RETA demonstrated superior effectiveness with remarkable and sustained weight loss, profound reductions in tumor engraftment, and significantly reduced tumor burden compared to SEMA, WM-CR, and Veh

Retatrutide Retatrutide operates through triple receptor engagement targeting GLP-1, GIP, and glucagon receptors

The Bigger Picture Side effects are a normal part of starting GLP-1 therapy for most people

Eur J Pharm Sci (2019) 128:10311